Back to results
US 2024/0192216 A1Published application
Metabolic biomarker set for assessing ovarian cancer
AssigneeBiocrates Life Sciences AG
InventorsUdo MÜLLER, Simon SCHAFFERER, Barbara BURWINKEL
Life of this patent
Estimating the term…
Abstract
The present invention relates to new biomarkers for assessing ovarian cancer being more sensitive, particularly at early stage of disease. Moreover, the present invention relates to a method for assessing ovarian cancer from a patient to be examined, and to a kit for carrying out the method.
Claims14
-13. (canceled)
A metabolic biomarker set for assessing ovarian cancer comprising at least
- i.) one amino acid selected from the group of alanine, arginine, histidine, tryptophan, glutamate, and
- ii.) one phospholipid selected from the group of lyso PC a C18:1, lyso PC a C18:2, and PC aa C32:2,
- iii.) one acylcarnitine selected from the group of acylcarnitine C18:1, acylcarnitine C18:2, and optional
- iv.) one sphingolipid SM(OH)C24:1.
1 more element
A method for assessing ovarian cancer, characterized in that obtaining a sample, preferably blood and/or plasma, from a patient to be examined and determining in the sample the amount of at least
- i.) one amino acid selected from the group of alanine, arginine, histidine, tryptophan, glutamate, and
- ii.) one phospholipid selected from the group of lyso PC a C18:1, lyso PC a C18:2, and PC aa C32:2, and
- iii.) one acylcarnitine selected from the group of acylcarnitine C18:1, preferably acylcarnitine C18:2,
- and optional
- iv.) one sphingolipid SM(OH)C24:1 are determined,
- and wherein at least one ratio of at least two biomarkers of i.) to iv.) is determined.
3 more elements
Dependencies are inferred from the claim text.